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Abstract
Background: The purpose of this study was to develop an effective nomogram capable of estimating the individual
survival outcomes of patients with hepatocellular carcinoma (HCC), and compare the predictive accuracy and
discriminative ability with other staging systems.
Methods: The nomogram was established based on a retrospective study of 661 patients newly diagnosed with HCC
at the Beijing Ditan Hospital (Beijing, China), Capital Medical University, between October 2008 and July 2012. The
predictive accuracy and discriminative ability of the previously developed nomogram were assessed by C-index and
calibration curves, and were compared to seven current commonly used staging systems. The results were validated,
using a bootstrap approach to correct for bias, in a prospective study of 220 patients consecutively enrolled between
August 2012 and March 2013.
Results: Multivariate analysis of the primary cohort for survival analysis identified the independent factors to be aspartate
aminotransferase, ɣ-glutamyl transpeptidase, white blood cell count, neutrophil-to-lymphocyte ratio, prothrombin activity,
α-fetoprotein, tumor number and size, lymph node metastasis, and portal vein involvement, which were all included to
build the nomogram. The calibration curve for predicting the probability of survival showed consistency between the
nomogram and the actual observation. The C-index of the nomogram was 0.81 (95% confidence interval, 0.79–0.82),
which was statistically better than that of the Tumor, Node, Metastasis staging (0.71), Barcelona Clinic Liver Cancer
staging (0.77), Okuda (0.62), Japan Integrated Staging (0.73), Cancer of the Liver Italian Program score (0.76), Chinese
University Prognostic Index (0.68), and the Groupe d’ Etude et de Traitement du Carcinome Hepatocellulaire
Prognostic classification (0.65) (p < 0.001 for all). The results were validated in the prospective validation cohort.
Conclusions: The prognostic nomogram resulted in more accurate individualized risk estimates for overall survival in
HCC patients.
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Background
Hepatocellular carcinoma (HCC) is the fifth most
common malignancy and the second highest mortality
rate among cancers worldwide, accounting for more
than 0.5 million deaths annually [1]. Furthermore, the
incidence of HCC has been increasing in the last
decades [2, 3]. Therefore, HCC has been a major health
problem worldwide. In the past decades, several effective
therapies have been developed, including surgical resec-
tion, liver transplantation, radiofrequency ablation
(RFA), microwave ablation, percutaneous ethanol injec-
tion (PEI), and transcatheter arterial embolization or
chemoembolization (TAE/TACE) [4]. Therefore, it is im-
perative to determine whether a patient would benefit
from aggressive therapies, while avoiding overtreatment.
Cancer staging is important for guiding therapeutic
interventions and assessing prognosis that could be of
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significance for both the patients and clinicians in
decision-making.
Currently, several staging systems are being used to pre-
dict survival in HCC patients, including the Tumor, Node,
Metastasis (TNM) staging [5], Barcelona Clinic Liver
Cancer (BCLC) staging [6], Okuda [7], Cancer of the Liver
Italian Program (CLIP) score [8], Japan Integrated Staging
Score (JIS) [9], Chinese University Prognostic Index
(CUPI) [10], and the Groupe d’ Etude et de Traitement du
Carcinome Hepatocellulaire Prognostic classification
(GETCH) [11], all of which have their advantages and
disadvantages. The Okuda, CUPI, and GETCH classifica-
tions properly stratified the prognosis of patients with
advanced or terminal stage [12]. The TNM staging only
accounts for tumor-related indicators reflecting the tumor
morphology and pathology, without taking the liver func-
tional features into consideration [13]. Meanwhile, these
staging systems only serve to stratify patients into various
groups with variable outcomes, but could not estimate the
individual survival outcomes of HCC.
Nomograms are graphic calculating scales of predictive
statistical models to optimize predictive accuracy of indi-
viduals [14, 15], and they have been developed for
several carcinomas [16–19]. Because nomograms has
been demonstrated to provide more precise prediction
over the traditional staging systems in many types of
cancers, it has been proposed as an alternative method
or even as a new standard to guide the administration of
appropriate treatment to cancer patients [16, 19, 20].
However, nomograms that predict overall survival (OS)
in HCC patients are rare. Although Li shu et al. pro-
posed a prognostic nomogram specifically developed for
patients with unresectable HCCs after TACE, it did not
cover the entire clinical spectrum of HCCs [21]. Patients
who were suitable candidates for surgical resection or
had advanced/end-stage cancers were excluded. In this
study, the specific aim of this analysis was to develop a
simple and clinically useful nomogram for patients with
HCC and compare the performance of this model with
the currently available staging systems.
Methods
Patients and design
We retrospectively analyzed 661 patients between
October 2008 and July 2012 and prospectively studied 220
patients between August 2012 and March 2013, who were
newly diagnosed with HCC at the Beijing Ditan Hospital
(Beijing, China), Capital Medical University. The diagnosis
of HCC was based on the European Association for the
Study of the Liver (EASL) criteria [22]: a histopathologic
confirmation, a positive lesion detected by at least 2 differ-
ent imaging techniques, or a positive lesion detected by 1
imaging technique combined with α-fetoprotein
(AFP) >400 ng/ml. The imaging techniques included
transabdominal ultrasonography, angiogram, com-
puted tomography (CT) and magnetic resonance
imaging (MRI). Patient records and information was
anonymized prior to analysis. This project was
approved by the ethics committee of the Beijing
Ditan Hospital (Beijing, China).
The inclusion criteria were age 18–75 years; newly
diagnosed with HCC; and no history of previous anti-
cancer therapy. The exclusion criteria were the diagnosis
or history of other malignancies; tumors of uncertain
origin or probable metastatic liver tumors; patients with
missing key data concerning clinical information and
laboratory data; or patients with no follow-up data.
Resection and liver transplantation should be the first op-
tion for patients who have the optimal profile. Locoregional
approaches including ablation and TAE were used for
patients who were not suitable candidates for curative ther-
apies. RFA, PEI, or microwave ablation was performed in
HCC patients with 2–3 nodules ≤3 cm. TACE/Lp-TAE
were performed in patients with 4 nodules >3 cm, or
Child-Pugh A or B. Sorafenib and FOLFOX regimens were
considered first-line treatment in patients with distant
metastases who can no longer be treated with potentially
more effective therapies. End stage includes those patients
with severe impairment of liver function (Child-Pugh C)
merely received the best supportive care [23, 24].
Data collection
A standardized data collection form was designed to re-
trieve all the relevant information on demographic data
(age, sex, history of smoking, history of alcohol
consumption, family history of HCC, and household
registry); laboratory data (alanine aminotransferase
[ALT], aspartate aminotransferase [AST], total bilirubin
[TBil], serum albumin [ALB], alkaline phosphatase
[ALP], ɣ-glutamyl transpeptidase [GGT], prothrombin
activity [PTA], international normalized ratio [INR],
AFP, white blood cell [WBC] count, absolute neutrophil
count [NC], absolute lymphocyte count [LC], absolute
platelet count [PLT], neutrophil-to-lymphocyte ratio
[NLR]); and tumor-related indicators (tumor size and
number, lymph node metastasis, distant metastasis,
portal vein involvement). The relevant data were
collected from the patient medical records or the
hospital database at the time of HCC diagnosis and dur-
ing the follow-up period. In addition, seven scoring
systems associated with clinical prognosis were used at
baseline, which were the TNM, BCLC, Okuda, CLIP, JIS,
CUPI, and GETCH staging scores, as previously
described [5–11].
Follow-up
All patients were followed-up at least once every
3 months during the first 2 years after treatment, and
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every 4–6 months annually thereafter. At each of these
follow-up visits, a detailed history was taken and a
complete physical examination was carried out. Abdominal
CT or MRI was also done annually or earlier when tumour
recurrence/metastasis was suspected. OS was defined as
the interval between diagnosis and death from any cause or
until the last known follow-up, obtained from the patient
medical records, or through direct contact with the patients
or their families.
Statistical analysis
All the statistical analyses were conducted with SPSS
20.0 statistical package (IBM, Armonk, NY, USA).
Continuous variables were presented as mean ± standard
deviation or medians with interquartile ranges, while
categorical variables as the frequencies or percentages of
events. The Student’s t-test or Mann–Whitney U test
was used for continuous data. The Pearson chi-square
or Fisher’s exact tests were used to compare differences
in proportion between the groups, as appropriate. Cox
univariate and multivariate regression analyses were
performed to identify independent risk factors for
predicting mortality.
Nomograms were formulated based on the results of
the multivariate Cox regression analyses performed
using the RMS packages [25] in R version 3.0.2 (http://
www.r-project.org/). Final selection of the nomogram
model was based on a backward step-down process with
the Akaike information criterion [26]. The performance
of the nomograms and other seven staging systems for
predicting survival were evaluated by the concordance
index (C-index), an equivalent variable of the area under
curve (AUC) of the receiver operating characteristic
(ROC) curve for censored data. The maximum C-index
value is 1.0, which indicates a perfect prediction model
whereas 0.5 indicates a random chance to correctly pre-
dict outcome by the model. Bootstraps with 1,000
resamples were used for validation to correct the C-
index and explain the variance due to over-optimism.
Comparisons between nomogram models and the other
seven staging systems were performed with the rcorrp.-
cens function in the Hmisc package [27] in R. Calibra-
tion curves of the nomogram for 1-, 2-, and 3-year OS
were applied to assess the agreement between the pre-
dicted survival and the observed survival. Clinical sur-
vival outcomes were assessed by Kaplan–Meier analysis
and prognostic groups were compared by log-rank test.
When externally validating the nomogram, the total
points for each patient were computed according to the
established nomogram, which were used as factors in
the Cox regression model, and the C-index and calibra-
tion curves were derived based on the regression ana-
lysis. All statistical tests were two-sided with a statistical
significance level set at p values < 0.05.
Results
Patient characteristics and outcomes
In total, 1221 patients newly diagnosed with HCC
during the study period were enrolled in the study. Fol-
lowing the exclusion of those who did not meet the
inclusion criteria, 661 patients were finally included in
the primary cohort, and 220 in the prospective valid-
ation cohort. The baseline characteristics of the primary
and validation cohorts are listed in Table 1. 356 (40.4%)
of the patients had survived, whereas 525 (59.6%) of the
patients had died by the end of the 3-year follow-up.
The median OS periods were 25.0 months and
21.0 months for the primary and validation cohorts,
respectively. The 1-, 2-, and 3-year OS rates were 66.1,
50.8, and 41.6% in the primary cohort, and 63.6, 42.3,
and 36.4% in the prospective validation cohort,
respectively.
Univariate and multivariate analyses in the primary
cohort
For OS, the significant inferior prognostic factors in-
cluded the male sex, history of alcohol consumption,
ALT, AST, TBil, ALB, ALP, GGT, WBC, NC, LC, NLR,
Cr, PTA, AFP ≥ 400 ng/mL, tumor number ≥ 3, tumor
diameter ≥ 5 cm, lymph node metastasis, and portal vein
involvement (p < 0.05). The above variables were entered
into multivariate Cox proportional hazard regression
analyses. The results indicated AST, GGT, WBC, NLR,
PTA, AFP ≥ 400 ng/mL, tumor number ≥ 3, tumor diam-
eter ≥ 5 cm, lymph node metastasis, and portal vein involve-
ment to be independent prognostic variables. The detailed
results of the multivariate analysis are shown in Table 2.
Prognostic nomogram for survival
The coefficients obtained from the Cox regression
model were used to construct the nomograms for OS
(Fig. 1). Each subtype within the variables was
assigned a score. By adding up the total score from
all the variables and locating it to the total point
scale, we could determine the probabilities of the out-
comes by drawing a vertical line to the total score.
The nomograms included three liver function indices
(AST, GGT, PTA), two inflammatory indices (WBC,
NLR), and five tumor-related indicators (AFP, tumor
number, tumor size, lymph node metastasis, and
portal vein involvement), of which PTA, NLR, and
portal vein involvement were the most important
contributing factors for OS prediction. Details con-
cerning the point assignment from the nomograms
and the prognostic score are shown in Table 3.
Validation of the prognostic nomogram
The C-index for the established nomogram for predicting
the OS was 0.81 (95% confidence interval (CI), 0.79–0.82)
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in the primary cohort. When the validation cohort was
subjected to the nomogram, the C-index was 0.78 (95%
CI, 0.74–0.82), which was greater than 0.7, suggesting the
suitability of the new model for patients with HCC. The
calibration plots showed fair agreements between the
nomogram predictions and actual observations for the 1-,
2-, and 3-year OS in the primary cohort (Fig. 2a-c) and
the prospective validation cohort (Fig. 2d-f).
According to the total scores, patients were divided
into four quartiles (quartile 1: 0–7; quartile 2: 8–10;
quartile 3: 10–15; and quartile 4: > 15). After dividing
the survival rates into quartiles, we further identified the
prognostic discrimination of the nomograms by Kaplan–
Meier analysis. The nomogram could accurately stratify
patients into the 4 risk groups with significant differ-
ences in the 1-, 2-, and 3-year OS rates in the primary
Table 1 Patient demographics and clinical characteristics
Patient’s Characteristics Total Primary cohort Prospective validation cohort p value
(n = 881) (n = 661) (n = 220)
Patient background
Age, yr 54.5 ± 10.0 54.4 ± 10.0 54.7 ± 9.9 0.746
Gender (Male/Female) 737/144 (83.7%/16.3%) 551/110 (83.4%/16.6%) 186/34 (84.6%/15.4%) 0.680
Family history of HCC (Yes/No) 115/766 (13.0%/87.0%) 85/576 (12.9%/87.1%) 30/190 (13.6%/86.4%) 0.767
History of smoking (Yes/No) 342/539 (38.8%/61.2%) 254/407 (38.4%/61.6) 88/132 (40.0%/60.0%) 0.678
History of alcohol use (Yes/No) 344/537 (39.0%/61.0%) 262/399 (39.6%/60.4%) 82/138 (37.3%/62.7%) 0.534
Cirrhosis (Yes/No) 720/161 (81.7%/18.3%) 536/125 (81.1%/18.9%) 184/36 (83.6%/16.4%) 0.397
Cause of HCC
Hepatitis B (Yes/No) 780/101 (88.5%/11.5%) 582/79 (88.0%/12.0%) 198/22 (90.0%/10.0%) 0.431
Hepatitis C (Yes/No) 69/812 (7.8%/92.2%) 52/609 (7.9%/92.1%) 17/203 (7.7%/92.3%) 0.947
Alcohol Liver (Yes/No) 121/760 (13.7%/86.3%) 94/567 (14.2%/85.8%) 27/193 (12.3%/87.7%) 0.467
other cause (Yes/No) 3/878 (0.3%/99.7%) 3/658 (0.4%/99.6%) 0/220 (0.0%/100.0%) 0.578
Laboratory data
ALT, IU/L 36.5 (24.8,59.4) 36.4 (24.8,60.1) 36.5 (24.7,57.6) 0.972
AST, IU/L 45.3 (29.8,74.2) 45.6 (29.4,75.7) 42.7 (30.0,69.9) 0.450
TBIL, μmol/L 20.2 (13.5,31.1) 21.0 (14.2,33.4) 17.3 (12.5,25.8) <0.001
ALB, g/L 36.6 ± 6.9 36.4 ± 7.2 37.1 ± 6.2 0.165
ALP, IU/L 123.9 ± 82.0 124.9 ± 82.3 121.0 ± 81.1 0.552
GGT, IU/L 64.3 (30.8,138.3) 60.6 (29.9,133.7) 71.5 (37.1,143.9) 0.042
WBC, 109/L 4.7 ± 1.9 4.6 ± 1.9 4.8 ± 2.0 0.269
NC, 109/L 2.9 ± 1.5 2.9 ± 1.5 3.0 ± 1.5 0.554
LC, 109/L 1.23 ± 0.61 1.20 ± 0.61 1.30 ± 0.59 0.042
PLT, 109/L 112.3 ± 67.9 109.2 ± 64.5 121.5 ± 76.8 0.034
NLR 2.9 ± 2.0 2.9 ± 2.0 2.7 ± 1.8 0.255
Cr, μmoI/L 70.5 ± 31.9 71.7 ± 35.2 66.8 ± 18.3 0.008
PTA, % 75.7 ± 18.6 74.8 ± 18.8 78.4 ± 17.4 0.012
INR 1.2 ± 1.6 1.2 ± 1.8 1.2 ± 0.3 0.453
AFP, ng/mL (<400/ ≥ 400) 221/660 (25.1%/74.9%) 161/500 (24.4%/75.6%) 60/160 (27.3%/72.7%) 0.388
Tumor-related indicators
Tumor number (<3/ ≥ 3) 310/556 (35.8%/64.2%) 220/432 (33.7%/66.3%) 90/124 (42.1%/57.9%) 0.028
Tumor size,cm (<5/ ≥ 5) 262,537 (32.8%/67.2%) 192/415 (31.6%/68.4%) 70/122 (36.5%/63.5%) 0.214
Lymph node metastasis (Yes/No) 79/802 (9.0%/91.0%) 54/607 (8.2%/91.8%) 25/195 (11.4%/88.6%) 0.151
Portal vein involvement (Yes/No) 227/654 (25.8%/74.2%) 164/497 (24.8%/75.2%) 63/157 (28.6%/71.4%) 0.261
Data are presented as n (%), mean ± SD, or median (interquartile range)
Abbreviations: ALT alanine aminotransferase, AST aspartate aminotransferase, TBil total bilirubin, ALB serum albumin, ALP alkaline phosphatase, GGT ɣ-glutamyl
transpeptidase, WBC white blood cell count, NC absolute neutrophil count, LC absolute lymphocyte count, PLT platelet count, NLR neutrophil-lymphocyte ratio,
Cr serum creatinine, PTA prothrombin activity, INR international normalized ratio, AFP alpha fetoprotein
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(3-year OS rate: 76.2% in quartile 1, 65.6% in quartile 2,
25.7% in quartile 3, and 3.2% in quartile 4; p < 0.001)
and the validation cohort (3-year OS rate: 64.6% in quar-
tile 1, 55.1% in quartile 2, 28.6% in quartile 3, and 0% in
quartile 4; p < 0.001) (Fig. 3h,p).
The performance of the nomogram compared to other
staging systems
As shown in Fig. 3a-p, the Kaplan–Meier curves were
generated for all the staging systems in the primary and
validation cohorts. Although all the staging systems
showed good prognostic stratification (p < 0.001 for all
cases) in the primary cohort, some overlapping of the
survival curves for TNM, BCLC, JIS, and CLIP was
observed. In the validation cohort, all the staging
systems also showed clear prognostic stratification
(p < 0.001); however, some overlapping of the survival
curves was observed for the TNM, BCLC, Okuda,
JIS, and CLIP. In both cohorts, the TNM staging
was not good at stratifying patients with stage III–
IV, and the BCLC was not good at stratifying the pa-
tients between stages C and D. Moreover, the
Okuda, CUPI, and the GETCH classifications could
stratify patients with stage I–III to a certain extent,
whereas they were unsatisfactory in stratifying
patients in the early stages of HCC in both cohorts.
Our nomogram displayed better accuracy in predicting
survival of patients with HCC in both cohorts. As shown
in Table 4, the nomogram for OS had a bootstrap-
corrected C-index of 0.81, which was significantly better
than that of the TNM (0.71), BCLC (0.77), Okuda (0.62),
JIS (0.62), CLIP (0.76), CUPI (0.68), and GETCH (0.65)
Table 2 Univariate and multivariate Cox regression analyses for OS in patients with HCC from the primary cohort (n = 661)
Univariate analysis Multivariate analysis
HR (95% CI) p value HR (95% CI) p value
Factors Selected
AST, IU/L 1.00 (1.00-1.00) <0.001 1.01 (1.00-1.01) 0.010
GGT, IU/L 1.00 (1.00-1.00) <0.001 1.01 (1.00-1.01) 0.001
WBC, 109/L 1.16 (1.10-1.22) <0.001 1.09 (1.02-1.16) 0.007
NLR 1.33 (1.28-1.38) <0.001 1.15 (1.10-1.21) <0.001
PTA, % 0.98 (0.97-0.98) <0.001 0.98 (0.97-0.99) <0.001
AFP≥ 400 ng/mL 2.82 (2.28-3.49) <0.001 1.36 (1.06-1.76) 0.017
Tumor number≥ 3 2.19 (1.79-2.69) <0.001 1.27 (1.01-1.61) 0.044
Tumor size≥ 5 cm 3.12 (2.52-3.86) <0.001 1.56 (1.22-1.99) <0.001
Lymph node metastasis 4.22 (3.12-5.72) <0.001 1.66 (1.18-2.34) 0.004
Portal vein involvement 9.45 (7.48-11.95) <0.001 4.85 (3.62-6.49) <0.001
Factors not Selected
Age, yr 0.99 (0.98-1.00) 0.075
Male 0.75 (0.57-1.00) 0.047
Familyhistory of HCC 1.16 (0.87-1.55) 0.310
History of smoking 1.17 (0.96-1.44) 0.127
History of alcohol use 1.46 (1.19-1.79) <0.001
ALT, IU/L 1.00 (1.00-1.00) 0.033
TBIL, μmol/L 1.01 (1.01-1.01) <0.001
ALB, g/L 0.96 (0.95-0.98) <0.001
ALP, IU/L 1.00 (1.00-1.01) <0.001
NC, 109/L 1.36 (1.28-1.45) <0.001
LC, 109/L 0.55 (0.46-0.67) <0.001
PLT, 109/L 1.00 (1.00-1.00) 0.060
Cr, μmoI/L 1.00 (1.00-1.01) <0.001
INR 1.01 (0.96-1.05) 0.795
Abbreviations: ALT alanine aminotransferase, AST aspartate aminotransferase, TBil total bilirubin, ALB serum albumin, ALP alkaline phosphatase, GGT ɣ-glutamyl
transpeptidase, WBC white blood cell count, NC absolute neutrophil count, LC absolute lymphocyte count, PLT platelet count, NLR neutrophil-lymphocyte ratio, Cr
serum creatinine, PTA prothrombin activity, INR international normalized ratio, AFP alpha fetoprotein, HR hazard ratio, CI confidence interval
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Fig. 1 A hepatocellular carcinoma survival nomogram is depicted. To use the nomogram, the value of an individual patient is located on each variable
axis, and a line is drawn upward to determine the number of points received for the value of each variable. The sum of these numbers is located on the
total point axis, and a line is drawn downward to the survival axes to determine the likelihood of 1-, 2-, and 3-year survivals. AST, aspartate aminotransferase;
GGT, γ-glutamyl transpeptidase; WBC, white blood cell; NLR, neutrophil-to-lymphocyte ratio; PTA, prothrombin activity; AFP, alpha fetoprotein
Table 3 Point assignment from nomograms and prognostic scores
Liver function index Inflammatory index Tumor index Points
AST Points GGT Points PTA Points WBC Points NLR Points
0 0 0 0 10 10 1 0 0 0 AFP
100 1 100 1 20 9 2 0 1 1 <400 0
200 1 200 1 30 8 3 1 2 1 ≥400 1
300 2 300 2 40 8 4 1 3 2 Lymph node metastasis
400 2 400 2 50 7 5 1 4 2 No 0
500 3 500 3 60 6 6 2 5 3 Yes 2
600 3 600 4 70 5 7 2 6 3 Portal vein involvement
700 4 700 4 80 5 8 2 7 4 No 0
800 4 800 5 90 4 9 3 8 4 Yes 6
900 5 900 5 100 3 10 3 9 5 Tumor number
1000 5 110 2 11 3 10 6 <3 0
1100 6 120 2 11 6 ≥3 1
1200 6 130 1 12 7 Tumor size
140 0 13 7 <5 0
14 8 ≥5 2
Abbreviations: AST aspartate aminotransferase, GGT ɣ-glutamyl transpeptidase, WBC white blood cell count, NLR neutrophil-lymphocyte ratio, PTA prothrombin
activity, AFP alpha fetoprotein
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staging systems in the primary cohort (p < 0.001 for all).
In the prospective validation cohort, the nomograms
had the highest areas under the curve (0.78), but without
statistical significance only in comparison to BCLC.
Discussion
In this study, we established a novel, easy-to-use, and ef-
fective nomogram capable of estimating individual sur-
vival outcomes for HCC. Moreover, a robust HCC
nomogram including the inflammatory indices (WBC,
NLR) was developed to improve the predictive power of
the current prognostic scores.
Distinct from other solid cancers, the prognosis for
HCC patients relies not only on tumor progression but
also on the extent of liver dysfunction; approximately 70
to 90% of HCCs occur in the context of chronic liver in-
flammation and cirrhosis [28, 29]. Consequently, staging
systems such as TNM that depend solely on pathological
characteristics retain limited prognostic impact on HCC
[13]. A number of alternative systems have been
proposed for HCC, including the BCLC, CLIP, CUPI,
and JIS. However, there is no universally accepted
consensus about the best staging system for predicting
the outcome of HCC patients.
Numerous clinical and experimental data demon-
strated that host inflammatory response to cancer cells
is associated with tumor progression [30, 31]. The link
between inflammation and cancer is well established.
Various markers of systemic inflammation response, in-
cluding WBC count [32, 33], cytokines [34, 35], and
absolute count of blood neutrophils or lymphocytes
as well as the neutrophil-to-lymphocyte (NLR) ratio
[36–38] have been explored for their prognostic im-
pact in various cancer populations including HCC. In
this study, we also found that the WBC count and
NLR have moderate contributions to the nomogram
prediction of OS. Elevated neutrophils are regarded as
a reservoir of the circulating vascular endothelial
growth factor, which plays a key role in the promo-
tion of angiogenesis [39], and neutrophils could
contribute to metastasis by promoting the motility of
tumor cells and the adhesion of metastatic tumor
cells to liver sinusoids [40, 41]. Conversely, reduced
lymphocyte infiltration, reflecting the suppression of
Fig. 2 The calibration curve of overall survival at 1, 2, and 3 years for the primary cohort (a-c) and the prospective validation cohort (d-f).
Nomogram-predicted probability of survival is plotted on the x-axis, and the actual survival is plotted on the y-axis. Dashed lines along the 45°
line through the point of origin represent the perfect calibration models where the predicted probabilities are identical to the actual probabilities
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the host immune surveillance, has been shown to
attenuate lymphocyte-mediated antitumor immune
response [42]. The presence of high intratumoral acti-
vated CD8 cytotoxic cells is associated with improved
survival in HCC patients [43]. Consequently, when
taken together, NLR could reflect the balance between
host inflammation and immunity, which has been re-
ported to be a predictor of survival in HCC patients
who underwent hepatic resection, RFA, TACE, and
liver transplantation [36, 44–46]. In the future,
manipulating the inflammatory status and the im-
mune function of HCC patients might be a promising
strategy for further improving the clinical outcomes.
The proposed nomogram included three liver function
indices (AST, GGT, PTA), five tumor-related indicators
(AFP, tumor number and size, lymph node metastasis,
and portal vein involvement), and two inflammatory
indices (WBC, NLR), which performed well in predicting
the survival outcome of HCC patients, and the predic-
tion was supported by the C-index (0.82 and 0.78 for the
primary and validation cohorts, respectively) and the
calibration curves. In the current study, the nomogram
showed the highest predictive accuracy for OS in
patients with HCC, compared to the other seven staging
systems. Although there was no statistical significance in
comparison to the BCLC in the validation cohort, it is
worth noting that the nomogram could more effectively
stratify patients with advanced stage cancers compared
to the TNM, BCLC, Okuda, and CLIP, and more effect-
ively stratify patients in the early stages of HCC than the
Okuda, CUPI, and GETCH in both cohorts.
Our nomogram has some limitations. First, the nomo-
gram was established based on a single-center cohort
study. Second, the nomograms only included basic
clinical and laboratory data. However, the present study
aimed to build reliable prediction models. Objective
variables are therefore the ideal factors to be included in
the models, while subjective variables might negatively
affect the models due to inevitable bias. Third, the study
was conducted retrospectively and selection bias might
exist. However, we have included a relatively large train-
ing cohort to build the nomograms and validated them
Fig. 3 Kaplan–Meier curves of risk group stratification for OS in the primary cohort (a-h) and the prospective validation cohort (i-p) categorized
according to different staging systems. a,i Tumor, Node, Metastasis (TNM); b,j Barcelona Clinic Liver Cancer (BCLC); c,k Okuda; d,l Japan Integrated
Staging Score (JIS); e,m Cancer of the Liver Italian Program (CLIP); f,n Chinese University Prognostic Index (CUPI); g,o Groupe d’ Etude et de
Traitement du Carcinome Hepatocellulaire Prognostic classification (GETCH); and h,p the prognostic nomogram
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by a prospective dataset. The results consistently showed
the satisfactory performance of the established models.
Conclusions
In conclusion, we developed and validated nomograms
predicting individual prognosis in patients with HCC.
The proposed nomogram in this study provided better
predictive accuracy and discrimination than the TNM,
BCLC, Okuda, JIS, CLIP, CUPI, and GETCH staging
systems, and it offers a useful tool for providing patient
counseling and timing surveillance, as well as clinical
assessments. In order to standardize the use of this
nomogram, validation with data from other institutions
and other patient groups is required.
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